Youngmee Kwon

2.7k total citations
78 papers, 2.1k citations indexed

About

Youngmee Kwon is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Youngmee Kwon has authored 78 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 43 papers in Oncology, 37 papers in Cancer Research and 20 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Youngmee Kwon's work include Breast Cancer Treatment Studies (30 papers), HER2/EGFR in Cancer Research (19 papers) and Breast Lesions and Carcinomas (18 papers). Youngmee Kwon is often cited by papers focused on Breast Cancer Treatment Studies (30 papers), HER2/EGFR in Cancer Research (19 papers) and Breast Lesions and Carcinomas (18 papers). Youngmee Kwon collaborates with scholars based in South Korea, United States and Singapore. Youngmee Kwon's co-authors include Jungsil Ro, Keun Seok Lee, Byung‐Ho Nam, In Hae Park, So‐Youn Jung, Seok Won Kim, Seeyoun Lee, Kyung Hwan Shin, Han‐Sung Kang and Eun Sook Lee and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer Research.

In The Last Decade

Youngmee Kwon

75 papers receiving 2.0k citations

Peers

Youngmee Kwon
Giuseppe Petrella Italy
H. Marsiglia France
Marc A. Bollet France
Silvana Di Palma United Kingdom
Christine Sagan France
Funda Meric United States
Fabiola Paiar Italy
Peter C. de Bruin Netherlands
Giuseppe Trifirò Italy
Frederick C. Koerner United States
Giuseppe Petrella Italy
Youngmee Kwon
Citations per year, relative to Youngmee Kwon Youngmee Kwon (= 1×) peers Giuseppe Petrella

Countries citing papers authored by Youngmee Kwon

Since Specialization
Citations

This map shows the geographic impact of Youngmee Kwon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Youngmee Kwon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Youngmee Kwon more than expected).

Fields of papers citing papers by Youngmee Kwon

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Youngmee Kwon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Youngmee Kwon. The network helps show where Youngmee Kwon may publish in the future.

Co-authorship network of co-authors of Youngmee Kwon

This figure shows the co-authorship network connecting the top 25 collaborators of Youngmee Kwon. A scholar is included among the top collaborators of Youngmee Kwon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Youngmee Kwon. Youngmee Kwon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Kwon, Youngmee, et al.. (2025). Benchmarking of dimensionality reduction methods to capture drug response in transcriptome data. Scientific Reports. 15(1). 32173–32173.
2.
You, Ji Young, Kyong Hwa Park, Eun Sook Lee, et al.. (2023). Determining the Factors Predicting the Response to Anti-HER2 Therapy in HER2-Positive Breast Cancer Patients. Cancer Control. 30. 2905559720–2905559720.
3.
Lee, Dong-Eun, Eun‐Gyeong Lee, Seeyoun Lee, et al.. (2023). Clinicopathological Factors Associated with Oncotype DX Risk Group in Patients with ER+/HER2- Breast Cancer. Cancers. 15(18). 4451–4451. 1 indexed citations
4.
You, Ji Young, et al.. (2023). Could axillary lymph node dissection be omitted in the mastectomy patient with tumor positive sentinel node?. Frontiers in Oncology. 13. 1181069–1181069. 1 indexed citations
5.
Cho, Soo Youn, So Yeon Park, Young Kyung Bae, et al.. (2021). Standardized Pathology Report for Breast Cancer. Journal of Breast Cancer. 24(1). 1–1. 10 indexed citations
6.
Ahn, Soomin, Ji Won Woo, Hyojin Kim, et al.. (2021). Programmed Death Ligand 1 Immunohistochemistry in Triple-Negative Breast Cancer: Evaluation of Inter-Pathologist Concordance and Inter-Assay Variability. Journal of Breast Cancer. 24(3). 266–266. 14 indexed citations
7.
Paik, Soonmyung, Youngmee Kwon, Moo Hyun Lee, et al.. (2021). Systematic evaluation of scoring methods for Ki67 as a surrogate for 21-gene recurrence score. npj Breast Cancer. 7(1). 13–13. 12 indexed citations
8.
Kim, Ji‐Hyun, Youngmee Kwon, Keun Seok Lee, et al.. (2019). Genomic Characteristics of Triple-Negative Breast Cancer Nominate Molecular Subtypes That Predict Chemotherapy Response. Molecular Cancer Research. 18(2). 253–263. 30 indexed citations
9.
Park, Soo Jin, Moo Hyun Lee, Sun‐Young Kong, et al.. (2018). Use of adjuvant chemotherapy in hormone receptor-positive breast cancer patients with or without the 21-gene expression assay. Breast Cancer Research and Treatment. 170(1). 69–76. 2 indexed citations
10.
Park, In Hae, Sun‐Young Kong, Jae Y. Ro, et al.. (2015). Prognostic Implications of Tumor-Infiltrating Lymphocytes in Association With Programmed Death Ligand 1 Expression in Early-Stage Breast Cancer. Clinical Breast Cancer. 16(1). 51–58. 74 indexed citations
11.
Im, Seock‐Ah, Keun Seok Lee, Jungsil Ro, et al.. (2011). Phase II trial of preoperative paclitaxel, gemcitabine, and trastuzumab combination therapy in HER2 positive stage II/III breast cancer: The Korean Cancer Study Group BR 07-01. Breast Cancer Research and Treatment. 132(2). 589–600. 9 indexed citations
12.
Jeong, Jae-Heon, So‐Youn Jung, In Hae Park, et al.. (2010). Predictive factors of pathologic complete response and clinical tumor progression after preoperative chemotherapy in patients with stage II and III breast cancer. Investigational New Drugs. 30(1). 408–416. 11 indexed citations
13.
Lee, Keun Seok, Jungsil Ro, Eun Sook Lee, et al.. (2009). Primary systemic therapy with intermittent weekly paclitaxel plus gemcitabine in patients with stage II and III breast cancer: a phase II trial. Investigational New Drugs. 28(1). 83–90. 13 indexed citations
14.
Ro, Jungsil, et al.. (2008). Trastuzumab treatment beyond brain progression in HER2-positive metastatic breast cancer. Annals of Oncology. 20(1). 56–62. 101 indexed citations
15.
Kim, Sun Jung, Ki‐Wook Chung, Dong‐Young Noh, et al.. (2004). Tamoxifen-resistant breast cancers show less frequent methylation of the estrogen receptor ? but not the estrogen receptor ? gene. Journal of Molecular Medicine. 83(2). 132–139. 38 indexed citations
16.
Lee, Ho Kyu, et al.. (2003). Inflammatory Pseudotumor of the Carotid Artery: Radiologic Findings. Journal of Computer Assisted Tomography. 27(2). 253–256. 6 indexed citations
17.
Kwon, Youngmee, Seung Kyu Lee, Jung‐Sun Kim, Jae Y. Ro, & Eunsil Yu. (2002). Synchronous Hepatocellular Carcinoma and Cholangiocarcinoma Arising in Two Different Dysplastic Nodules. Modern Pathology. 15(10). 1096–1101. 7 indexed citations
18.
Kwon, Youngmee, et al.. (1999). Clinical Analysis of Gamma Knife Radiosurgery for Brain Metastases.. Journal of Korean Neurosurgical Society. 28(5). 649–657. 2 indexed citations
19.
Kwon, Youngmee, et al.. (1999). Radiologic and Histopathologic Changes after Gamma Knife Radiosurgery for Acoustic Schwannoma. Stereotactic and Functional Neurosurgery. 72(1). 2–10. 35 indexed citations
20.
Kwon, Youngmee, et al.. (1998). Gamma Knife Treatment of Acoustic Neurinoma. Stereotactic and Functional Neurosurgery. 70(Suppl. 1). 57–64. 23 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Giuseppe Petrella Breakdown of academic impact, for papers by H. Marsiglia Breakdown of academic impact, for papers by Marc A. Bollet Breakdown of academic impact, for papers by Silvana Di Palma Breakdown of academic impact, for papers by Christine Sagan Breakdown of academic impact, for papers by Funda Meric Breakdown of academic impact, for papers by Fabiola Paiar Breakdown of academic impact, for papers by Peter C. de Bruin Breakdown of academic impact, for papers by Giuseppe Trifirò Breakdown of academic impact, for papers by Frederick C. Koerner
Rankless by CCL
2026